Bristol Eye Hospital

Bristol BS12LX

1 studies enrolling now · 27 studies all time

What they study most

Age-Related Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Dry Age-related Macular Degeneration, Eye Diseases, Geographic Atrophy, Geographic Atrophy Secondary to Age-related Macular Degeneration, Macular Atrophy, Macular Degeneration, Neovascular Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Retinal Degeneration

Studies at this site

• Extension Study for the Port Delivery System With Ranibizumab (Portal) — Recruiting now
• A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) — Recruiting now
• An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD — Completed
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease — Running, not enrolling
• A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema — Completed
• A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) — Completed
• FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD — Stopped early
• EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 — Stopped early
• A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema — Completed
• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration — Completed
• A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA) — Completed
• Non-proliferative Diabetic Retinopathy Treated With Runcaciguat — Completed
• A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment — Completed
• A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD) — Completed
• HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia — Completed
• A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy — Stopped early
• Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration — Completed
• Ranibizumab and Bevacizumab for Diabetic Macular Edema — Completed
• Minocycline to Treat Branch Retinal Vein Occlusion — Completed
• A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated. — Completed
• A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD) — Completed
• Minocycline to Treat Central Retinal Vein Occlusion — Completed
• Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration — Completed
• A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early
• A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early
• A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early
• Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT) — Stopped early